201 related articles for article (PubMed ID: 21771205)
1. Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice.
Elm T; Karpf DM; Øvlisen K; Pelzer H; Ezban M; Kjalke M; Tranholm M
Haemophilia; 2012 Jan; 18(1):139-45. PubMed ID: 21771205
[TBL] [Abstract][Full Text] [Related]
2. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A.
Martinowitz U; Bjerre J; Brand B; Klamroth R; Misgav M; Morfini M; Santagostino E; Tiede A; Viuff D
Haemophilia; 2011 Nov; 17(6):854-9. PubMed ID: 21443634
[TBL] [Abstract][Full Text] [Related]
3. A sensitive venous bleeding model in haemophilia A mice: effects of two recombinant FVIII products (N8 and Advate(®)).
Pastoft AE; Lykkesfeldt J; Ezban M; Tranholm M; Whinna HC; Lauritzen B
Haemophilia; 2012 Sep; 18(5):782-8. PubMed ID: 22500820
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and ex vivo whole blood clot formation of a new recombinant FVIII (N8) in haemophilia A dogs.
Karpf DM; Kjalke M; Thim L; Agersø H; Merricks EP; Defriess N; Nichols TC; Ezban M
Haemophilia; 2011 Sep; 17(5):e963-8. PubMed ID: 21682818
[TBL] [Abstract][Full Text] [Related]
5. Functional characteristics of N8, a new recombinant FVIII.
Christiansen ML; Balling KW; Persson E; Hilden I; Bagger-Sørensen A; Sørensen BB; Viuff D; Segel S; Klausen NK; Ezban M; Lethagen S; Steenstrup TD; Kjalke M
Haemophilia; 2010 Nov; 16(6):878-87. PubMed ID: 20546031
[TBL] [Abstract][Full Text] [Related]
6. Prolonged effect of a new O-glycoPEGylated FVIII (N8-GP) in a murine saphenous vein bleeding model.
Pastoft AE; Ezban M; Tranholm M; Lykkesfeldt J; Lauritzen B
Haemophilia; 2013 Nov; 19(6):913-9. PubMed ID: 23730746
[TBL] [Abstract][Full Text] [Related]
7. International comparative field study of N8 evaluating factor VIII assay performance.
Viuff D; Barrowcliffe T; Saugstrup T; Ezban M; Lillicrap D
Haemophilia; 2011 Jul; 17(4):695-702. PubMed ID: 21426445
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII.
Rea C; Dunkerley A; Sørensen B; Rangarajan S
Haemophilia; 2009 Nov; 15(6):1237-42. PubMed ID: 19664015
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A.
Meunier S; Alamelu J; Ehrenforth S; Hanabusa H; Abdul Karim F; Kavakli K; Khodaie M; Staber J; Stasyshyn O; Yee DL; Rageliene L
Thromb Haemost; 2017 Aug; 117(9):1705-1713. PubMed ID: 28692108
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of SCT800, a new recombinant FVIII, in hemophilia A mice.
Gu RL; Liu L; Xie LZ; Gai WL; Cao SS; Meng ZY; Gan H; Wu ZN; Li J; Zheng Y; Zhu XX; Dou GF
Acta Pharmacol Sin; 2016 Mar; 37(3):408-14. PubMed ID: 26806305
[TBL] [Abstract][Full Text] [Related]
11. The biological efficacy profile of BAX 855, a PEGylated recombinant factor VIII molecule.
Valentino LA; Cong L; Enockson C; Song X; Scheiflinger F; Muchitsch EM; Turecek PL; Hakobyan N
Haemophilia; 2015 Jan; 21(1):58-63. PubMed ID: 25459309
[TBL] [Abstract][Full Text] [Related]
12. Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model.
Rode F; Almholt K; Petersen M; Kreilgaard M; Kjalke M; Karpf DM; Groth AV; Johansen PB; Larsen LF; Loftager M; Haaning J
J Thromb Haemost; 2018 Jun; 16(6):1141-1152. PubMed ID: 29582559
[TBL] [Abstract][Full Text] [Related]
13. ReFacto and Advate: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A.
Di Paola J; Smith MP; Klamroth R; Mannucci PM; Kollmer C; Feingold J; Kessler C; Pollmann H; Morfini M; Udata C; Rothschild C; Hermans C; Janco R
Haemophilia; 2007 Mar; 13(2):124-30. PubMed ID: 17286764
[TBL] [Abstract][Full Text] [Related]
14. Continuous infusion during total joint arthroplasty in Japanese haemophilia A patients: comparison study among two recombinants and one plasma-derived factor VIII.
Takedani H
Haemophilia; 2010 Sep; 16(5):740-6. PubMed ID: 20398072
[TBL] [Abstract][Full Text] [Related]
15. Clinical observation on safety and efficacy of a plasma- and albumin-free recombinant factor VIII for on-demand treatment of Chinese patients with haemophilia A.
Zhang L; Zhao Y; Sun J; Wang X; Yu M; Yang R
Haemophilia; 2011 Mar; 17(2):191-5. PubMed ID: 20860578
[TBL] [Abstract][Full Text] [Related]
16. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
Deitcher SR; Tuller J; Johnson JA
Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
[TBL] [Abstract][Full Text] [Related]
17. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A.
Tiede A; Brand B; Fischer R; Kavakli K; Lentz SR; Matsushita T; Rea C; Knobe K; Viuff D
J Thromb Haemost; 2013 Apr; 11(4):670-8. PubMed ID: 23398640
[TBL] [Abstract][Full Text] [Related]
18. Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII.
Zollner S; Raquet E; Claar P; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
Thromb Res; 2014 Jul; 134(1):125-31. PubMed ID: 24814969
[TBL] [Abstract][Full Text] [Related]
19. Efficacy assessment of a new clotting factor concentrate in haemophilia A patients, including prophylactic treatment.
Den Uijl I; Mauser-Bunschoten EP; Roosendaal G; Schutgens R; Fischer K
Haemophilia; 2009 Nov; 15(6):1215-8. PubMed ID: 19686467
[TBL] [Abstract][Full Text] [Related]
20. Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(®) ) in patients with severe haemophilia A.
Klamroth R; Simpson M; von Depka-Prondzinski M; Gill JC; Morfini M; Powell JS; Santagostino E; Davis J; Huth-Kühne A; Leissinger C; Neumeister P; Bensen-Kennedy D; Feussner A; Limsakun T; Zhou M; Veldman A; St Ledger K; Blackman N; Pabinger I
Haemophilia; 2016 Sep; 22(5):730-8. PubMed ID: 27434619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
